Portfolio
Clinical Highlights
Fabi, Sabrina G. MD et al
DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study
AUGUST 2021
Green, Jeremy B. MD et al
A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines
AUGUST 2021
Faivre, Jimmy et al
Advanced Concepts in Rheology for the Evaluation of Hyaluronic Acid–Based Soft Tissue Fillers
JANUARY 2021
Cohen, Joel L. et al.
Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program
February 2021
Dermatologic Surgery – Glogau, Richard MD*; Kontis, Theda C. MD†
Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection
August 2021
Gary Monheit, M.D.
Efficacy and Safety of Two Resilient Hyaluronic Acid Fillers in the Treatment of Moderate-to-Severe Nasolabial Folds
August 2021
Joseph Jankovic M.D. et al
Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study
March 2018
Dermatologic Surgery – Hema Sundaram, MD, FAAD, Ava Shamban, et al.
Efficacy and Safety of a New Resilient Hyaluronic Acid Filler in the Correction of Moderate-to-Severe Dynamic Perioral Rhytides: A 52-Week Prospective, Multicenter, Controlled, Randomized, Evaluator-Blinded Study
December 2021
Glogau, Richard MD*; Kontis, Theda C. MD†
Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection
August 2021
Journal of the American Academy of Dermatology – Vince Bertucci, M.D.
DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)
December 2019
Dermatologic Surgery – Berthold Rzany, M.D. et al
Efficacy and Safety of 3 New Resilient Hyaluronic Acid Fillers, Crosslinked With Decreased BDDE, for the Treatment of Dynamic Wrinkles
October 2019
Plastic and Reconstructive Surgery – Jean Carruthers M.D. et al
DaxibotulinumtoxinA in the treatment of glabellar lines. Results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)
October 2019
Journal of Cosmetic Dermatology – Joely Kaufman-Janette MD et al.
Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate‐to‐severe nasolabial folds: A 64‐week, prospective, multicenter, controlled, randomized, double‐blind and within‐subject study
August 2019
Movement Disorders – Joseph Jankovic M.D. et al
Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study
March 2018
Dermatologic Surgery – Vince Bertucci M.D. et al
Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines. Additional Analyses From a Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Study Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines
December 2017
Dermatologic Surgery – Jean Carruthers M.D. et al
Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines. A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and Placebo
November 2017
Dermatologic Surgery – Enrique Garcia-Murray M.D. et al
Safety and Efficacy of RT002, an Injectable Botulinum Toxin Type A, for Treating Glabellar Lines
January 2015
Disclaimer
*DAXXIFY® (daxibotulinumtoxinA-Ianm) injection was approved by the FDA in 09/22 for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults and for the treatment of cervical dystonia in adults in 08/23. DAXXIFY® is currently being evaluated in additional therapeutic and aesthetic indications and was formerly known as RT002.